Worth reading
80Important
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
187200000
Yen (payment amount)Wording
Definitive
How definitive the wording is.Details of issuance or disposal
Issuance through a third-party allotment of the Sixth Series Unsecured Convertible Bonds with Stock Acquisition Rights
Who receives how much
698,220 shares (maximum number of shares to be delivered if all bonds are converted at the initial conversion price of ¥297.9)
Cantor Fitzgerald Europe (40 bonds)
The lower thin line represents the existing number of shares to which these shares will be added.
¥90 per ¥100 of the principal amount of each bond
Total issue value
Total principal amount of the bonds: ¥208,000,000; total payment amount: ¥187,200,000
Amount of funds to be raised
Total amount of ¥187,200,000 for the Sixth Series Convertible Bonds with Stock Acquisition Rights. Total payment amount for the entire financing: ¥1,411,681,050; estimated net proceeds: ¥1,369,681,050
Estimated issuance expenses
¥42,000,000 (for the entire financing)
Specific use of funds
Clinical development costs for the BTK inhibitor docirbrutinib (AS-1763), clinical development costs for the CDC7 inhibitor monzosertib (AS-0141), development costs for the preclinical pipeline, creation and research costs for development compounds, and working capital (general and administrative expenses for the company as a whole)
Existing Shares and Increase
+9.17%Rate of increase
20,652,469 shares22,546,455Shares
The ratio for the Sixth Series alone is Not disclosed. The Sixth, Fifth and Fourth Series Convertible Bonds with Stock Acquisition Rights represent 9.17% of the total number of issued shares and 9.18% of the total voting rights. Including the new shares issued in this financing, the ratios are 19.22% and 19.24% of total voting rights.
The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.
Terms of the stock acquisition rights
Exercise price
Initial conversion price: ¥297.9. There is no price adjustment provision. However, adjustment provisions apply for purposes including protection against dilution. There is no minimum conversion price.
Exercise period
From 26 November 2026 through 22 November 2029
Number of Stock Acquisition Rights
Total issued: 40 units. Unexercised balance: Not disclosed
Reason for acquisition without consideration
The company may acquire the bonds without consideration at its discretion if, among other circumstances, the need to strengthen its capital base ceases to exist in the future or a more favorable financing method becomes available.
Intended allottee's holding policy
Any transfer of these Convertible Bonds with Stock Acquisition Rights requires the company's prior written approval.
Payment date
25 November 2026
Basis for determining the amount to be paid
The conversion price is ¥297.9, representing 90% of the TSE closing price of ¥331 on 6 November 2026. The issue price of the bonds is ¥90 per ¥100 of principal, within the valuation range of ¥83.8 to ¥91.9 determined by an independent third-party institution.
Procedures under the Corporate Code of Conduct
A valuation was obtained from 株式会社赤坂国際会計, which is independent of the company and the proposed allottee, and an opinion was obtained from the Audit and Supervisory Committee (4 outside directors).
Most recent equity financing
Timing 28 September 2026 / Type Third-party allotment of the Fourth Series Unsecured Convertible Bonds with Stock Acquisition Rights and new shares / Amount Not disclosed, Timing 19 October 2026 / Type Third-party allotment of the Fifth Series Unsecured Convertible Bonds with Stock Acquisition Rights / Amount Not disclosed
Impact on Business Performance
The specific impact of this financing on operating results is Not disclosed
| Item | Details |
|---|---|
| Type of issuance or disposal | Issuance through a third-party allotment of the Sixth Series Unsecured Convertible Bonds with Stock Acquisition Rights |
| Number of shares to be issued or disposed of | 698,220 shares (maximum number of shares to be delivered if all bonds are converted at the initial conversion price of ¥297.9) |
| Issue price and disposal price | ¥90 per ¥100 of the principal amount of each bond |
| Total issue value | Total principal amount of the bonds: ¥208,000,000; total payment amount: ¥187,200,000 |
| Amount of funds to be raised | Total amount of ¥187,200,000 for the Sixth Series Convertible Bonds with Stock Acquisition Rights. Total payment amount for the entire financing: ¥1,411,681,050; estimated net proceeds: ¥1,369,681,050 |
| Estimated issuance expenses | ¥42,000,000 (for the entire financing) |
| Specific use of funds | Details Clinical development costs for the BTK inhibitor docirbrutinib (AS-1763), clinical development costs for the CDC7 inhibitor monzosertib (AS-0141), development costs for the preclinical pipeline, creation and research costs for development compounds, and working capital (general and administrative expenses for the company as a whole) / Amount Not disclosed / Scheduled timing of expenditures Not disclosed |
| Payment date | 25 November 2026 |
| Intended allottee | Cantor Fitzgerald Europe (40 bonds) |
| Intended allottee's holding policy | Any transfer of these Convertible Bonds with Stock Acquisition Rights requires the company's prior written approval. |
| Dilution Rate | The ratio for the Sixth Series alone is Not disclosed. The Sixth, Fifth and Fourth Series Convertible Bonds with Stock Acquisition Rights represent 9.17% of the total number of issued shares and 9.18% of the total voting rights. Including the new shares issued in this financing, the ratios are 19.22% and 19.24% of total voting rights. |
| Total number of issued shares | 20,652,469 shares (as of 30 June 2026) → 22,546,455 shares (if all of the Fourth through Sixth Series are converted)（9.17%） |
| Basis for determining the amount to be paid | The conversion price is ¥297.9, representing 90% of the TSE closing price of ¥331 on 6 November 2026. The issue price of the bonds is ¥90 per ¥100 of principal, within the valuation range of ¥83.8 to ¥91.9 determined by an independent third-party institution. |
| Exercise price | Initial conversion price: ¥297.9. There is no price adjustment provision. However, adjustment provisions apply for purposes including protection against dilution. There is no minimum conversion price. |
| Exercise period | From 26 November 2026 through 22 November 2029 |
| Number of Stock Acquisition Rights | Total issued: 40 units. Unexercised balance: Not disclosed |
| Reason for acquisition without consideration | The company may acquire the bonds without consideration at its discretion if, among other circumstances, the need to strengthen its capital base ceases to exist in the future or a more favorable financing method becomes available. |
| Procedures under the Corporate Code of Conduct | A valuation was obtained from 株式会社赤坂国際会計, which is independent of the company and the proposed allottee, and an opinion was obtained from the Audit and Supervisory Committee (4 outside directors). |
| Most recent equity financing | Timing 28 September 2026 / Type Third-party allotment of the Fourth Series Unsecured Convertible Bonds with Stock Acquisition Rights and new shares / Amount Not disclosed, Timing 19 October 2026 / Type Third-party allotment of the Fifth Series Unsecured Convertible Bonds with Stock Acquisition Rights / Amount Not disclosed |
| Impact on Business Performance | The specific impact of this financing on operating results is Not disclosed |
Items this document does not state (8)
Transfer restriction periodConditions for lifting transfer restrictionsCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioMajor shareholders after the offering
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To strengthen the financial base in order to provide continuous and stable funding for drug discovery research and development, and to fund the clinical development of docirbrutinib (AS-1763) and monzosertib (AS-0141), the preclinical pipeline, the creation and research of development compounds, and company-wide working capital.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.